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Abstract
Gaucher disease type 1 is caused by the defective activity of the lysosomal enzyme, acid b-glucosidase (GCase). Regular
infusions of purified recombinant GCase are the standard of care for reversing hematologic, hepatic, splenic, and bony
manifestations. Here, similar in vitro enzymatic properties, and in vivo pharmacokinetics and pharmacodynamics (PK/PD)
and therapeutic efficacy of GCase were found with two human GCases, recombinant GCase (CHO cell, imiglucerase, Imig)
and gene-activated GCase (human fibrosarcoma cells, velaglucerase alfa, Vela), in a Gaucher mouse, D409V/null. About
80+% of either enzyme localized to the liver interstitial cells and ,5% was recovered in spleens and lungs after bolus i.v.
injections. Glucosylceramide (GC) levels and storage cell numbers were reduced in a dose (5, 15 or 60 U/kg/wk) dependent
manner in livers (60–95%) and in spleens (,10–30%). Compared to Vela, Imig (60 U/kg/wk) had lesser effects at reducing
hepatic GC (p=0.0199) by 4 wks; this difference disappeared by 8 wks when nearly WT levels were achieved by Imig. Anti-
GCase IgG was detected in GCase treated mice at 60 U/kg/wk, and IgE mediated acute hypersensitivity and death occurred
after several injections of 60 U/kg/wk (21% with Vela and 34% with Imig). The responses of GC levels and storage cell
numbers in Vela- and Imig-treated Gaucher mice at various doses provide a backdrop for clinical applications and decisions.
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Introduction
In Gaucher disease, defective acid b-glucosidase (GCase) activity
leads to accumulation of its substrate, glucocerebroside (glucosylcer-
amide [GC]), in lysosomes of macrophages in many organs. This
results in the tissue appearance of characteristic storage cells,
Gaucher cells [1,2]. The pathologic accumulation of such storage
macrophages leads to the major manifestations including hepato-
splenomegaly, blood cytopenias, and bone marrow abnormalities
[1]. Deduve [3] was the first to suggest that reconstitution of
lysosomal enzyme activities could lead to clinical improvement.
Biochemical evidence to support this notion was derived from ex vivo
cross-correction of cells from patients with genetically distinct
mucopolysaccharide storage diseases in which intracellular storage
was reduced by cross-correcting soluble factors (enzymes) [4]. Based
on the concepts of receptor-mediated endocytosis through carbohy-
drate recognition receptors, enzyme replacement/reconstitution
therapy became a reality for Gaucher disease [5,6,7,8], using
mannosyl-terminated human placental GCase (alglucerase). Small
clinical trials showed improvement in the clinical and biochemical
features of the disease [5]. Later, recombinant a-mannosyl-
terminated human GCase (imiglucerase, Imig) was developed and
was shown to have biologic and therapeutic equivalency to
alglucerase [6,9]. This therapy has become the standard of care
for significantly involved patients with Gaucher disease type 1 [8].
Enzyme replacement therapy (ERT) has dramatically altered
the visceral phenotype of Gaucher disease and improved the
overall disease course in afflicted people [6,7,8]. For many affected
people the regular use of ERT improves the hepatosplenomegaly
within two years, accompanied by improvements in anemia and
thrombocytopenia [10]. Improvements in bone density [11,12],
bone pain, and crisis of avascular necrosis also occur [13]. ERT
also can restore normal growth patterns in the ,35% of children
with Gaucher disease and growth retardation [14]. Since 1991,
.5,000 individuals with Gaucher disease type 1 have received
regular infusions of a-mannosyl-terminated human GCase
[5,6,10,15,16,17]. A variety of doses and dosage schemes had
varying degrees of efficacy in hepatic, splenic, and bone marrow
involvement [10,16,18]. Detailed analyses of patients statistically
matched for phenotype demonstrated an incremental therapeutic
dose response with Imig, thereby providing data to facilitate
personalization of dosing regimens [18,19]. These advances have
been based primarily on clinical outcome measures of visceral and
hematologic resolution, with little data about the pharmacology
[20,21], tissue distribution, or cellular localization in the target
organs [22,23]. Histological and enzyme data in patients are
scarce due to the invasive nature of tissue sampling and the
inaccessibility of most tissues for systematic analyses. From a few in
vivo and autopsy studies, significant amounts of enzyme were
apparent in hepatic and/or splenic tissues for several days after
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and bone marrow mononuclear cells [15,24]. These results,
coupled with organ-specific therapeutic guidelines [25] provide
additional guidance for patients and their physicians and for new
innovative, adjunctive, and competitive therapies.
To date, most ERT data for Gaucher patients were obtained
from the use of Imig treatment. Imig is human recombinant
GCase that is secreted from Chinese hamster ovary (CHO) cells
with attached complex N-linked oligosaccharides. The purified
enzyme is then sequentially deglycosylated to expose ,3 a-
mannosyl residues on short N-linked oligosaccharide chains [26].
This modified enzyme has preferential distribution to and uptake
into macrophages via the macrophage mannose receptor [21]. In
addition, Imig has a single amino acid difference from the natural
sequence, by containing a histidine at residue 495 rather than an
arginine. Recently, GCase has been produced by gene activation
in a human fibrosarcoma cell line (velaglucerase alfa, Vela). To
achieve a-mannosyl residue exposure, these cells are treated with
kifunensine, an inhibitor of the a-mannosidase I that is present in
the endoplasmic reticulum [27]. This treatment leads to a GCase
with higher a-mannosyl content than the CHO-derived GCase,
since the natural sequential remodeling of the N-linked oligosac-
charides during transit through the Golgi is inhibited/prevented
[27]. In addition, Vela has the wild type sequence with an arginine
at position 495. Previously, the exchange of the histidine and
arginine at position 495 was shown to have no effect on any in vitro
physicokinetic properties [9,28], or on the crystal structure [17,29].
In general, ERT with GCase has a low infusion-related adverse
event profile [30,31]. Many of these are antibody (usually IgG)
mediated, and are managed by decreasing drug delivery rates or
cotreatment with antihistamines or, occasionally, corticosteroids.
In Gaucher disease, about 13–15% of patients developed an IgG
antibody response to alglucerase or Imig [32], whereas antibody
conversions were from 50–91% for the respective ERTs in other
lysosomal diseases [30]. Documented IgE-mediated or anaphy-
lactic reactions with Imig have been very infrequent (,1%), and
some patients were able to resume ERT following desensitization
or by using ramp-up infusion protocols [31].
The availability of mouse models that are analogues of visceral
Gaucher disease in humans allows for direct in vivo comparison of
the PK/PD and therapeutic effects [33] of different ERTs or other
therapeutic agents. Here, the biochemical properties, PK/PD, and
therapeutic effects of Vela and Imig were directly compared at
multiple doses. These studies also showed a complex uptake and
disappearance of exogenously administered enzyme that resulted
in a non-uniform tissue and cellular delivery of active enzyme.
Results
In vitro enzymology
GCase activity. Catalytic activities of Vela and Imig were
analyzed with 4MU-Glc and GC substrates. Vela had ,6–10%
reproducibly greater activity compared to Imig (Table 1). The
functional active sites of these two enzymes were quantified using
the single turnover substrate DNPFG, and consistent with the
hydrolytic activity, ,5–7% more functional active sites were
quantified with Vela than with Imig (Table 1). The respective Km
values for the 4 MU-Glc were 1.5960.2 or 1.6560.25 mM (n=6,
p=0.850).
Interaction of GCase and active site-directed inhibitors.
The reversible competitive and covalent active site-directed
(Conduritol B epoxide, CBE) inhibitors of GCase showed
comparable interaction with both enzymes [34,35,36] (Table 2).
IFG binding is of interest, since crystallization studies show that this
agent induces a significant conformational change and enhanced
enzyme stability [35]; similar changes are implied by comparable Ki
values. The IC50 or Ki values were similar for inhibitors of Vela and
Imig (p.0.05). The comparative pH profiles of these two enzymes
were similar in the range from pH 4.4–7.2. The peak activities were
at pH=5.4–5.6 (data not shown).
pH- and thermostabilities. The time-dependent stabilities
of Vela and Imig were evaluated at various temperatures and pH
values, as well as in either human or mouse serum. At pH=7.4 in
either citrate/phosphate buffer or mouse or human serum
(buffered to pH 7.4) at either 37 or 25uC, both enzymes showed
.50% irreversible losses of activity by 2 h; 70–85% losses were
observed by 4 h under the same conditions (p=0.99, Table 3).
Interaction with saposin C or BPS. Activation of Vela and
Imig by the negatively charged lipid, BPS, and saposin C was
determined in a detergent-free system with varying concentrations
of either agent. The activities of both enzymes increased by 5- to 6-
fold or 15- to 17-fold with saposin C (0 to 500 nM) or BPS (0 to
2 mM), respectively. In the presence of 0.5 mM of BPS either
GCase showed saturation kinetics with a maximum activation by
200 nM saposin C. Similarly, in the absence of saposin C, both
enzymes reacted maximal activation with 0.5 mM of BPS. No
significant differences were found in these responses (p=0.5875–
0.8473).
Protease susceptibility. The susceptibilities of Vela or Imig
to protease digestion were evaluated in vitro using Vela and Imig as
substrates for cathepsin D [29]. Using equal amounts of Vela or
Imig, cathepsin D (1 mg/ml) digestion led to ,72–76%
degradation of either enzyme after 4 h (data not shown). Both
enzymes were completely degraded within 4 h using 2 mg/ml
cathepsin D. There were no meaningful differences between the
susceptibilities of either enzyme to cathepsin D digestion.
Table 1. Vela and Imig active sites and specific activities.
Source Active sites GCase activity (nmole/h/mg)
2,4-DNPFG (n=8)
A NBD-GC (n=10)
A 4MU-Glc (n=6)
A
Imig 91.662.2% 1,191,610656,390 966,00068,467
Vela 97.460.6% 1,321,057667,237 1,030,48062,692
Amean 6 SE, Active sites are expressed as mole ratios of 2,4-DNP released and
enzyme protein.
doi:10.1371/journal.pone.0010750.t001
Table 2. Ki and IC50 values of GCase inhibitors for Vela and
Imig.
Inhibitor Vela Imig p value
Deoxynojirimycin (mM)* 23.4 27.4 0.8343
C4-Deoxynojirimycin (mM) 92.8 93.3 0.9692
C9-Deoxynojirimycin (nM) 88.1 66.9 0.8838
C12-Deoxynojirimycin (nM) 9.97 14.7 0.6957
Castanospermine (mM) 2.57 2.28 0.9972
Isofagomine (nM) 30.7 28.8 0.904
Conduritol B epoxide(mM)[IC50] 99.76 146.2 0.8775
*Ki values for all, except Conduritol B epoxide. Equal amounts of Vela or Imig
protein (8 pmol) were used. SE in all measurements was #20%.
doi:10.1371/journal.pone.0010750.t002
Gaucher Disease Mouse Model
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To determine the in vivo fate and stability of injected Vela or
Imig, the disappearance of either enzyme was evaluated in serum
and tissues. 9 V/null mice at 5 or 20 wks received intravenous
boluses of 60 U/kg of Vela or Imig. Serum and tissues were
harvested at 2 min to 42 h post-injection. Mice were perfused with
saline prior to collection to clear tissues of blood that potentially
contained exogenous GCase.
Serum GCase activities. The GCase activities in serum
from Vela- or Imig-injected 9 V/null mice (n=3) were
determined at each time point. Total blood volume in a mouse
was estimated as ,7% of body weight [37], and the serum yield is
about 50% of blood volume. Based on these estimates, both 5- and
20-wk 9 V/null mice showed that about 60–65% of the injected
enzyme (Vela and Imig) activities was recovered in serum at 2 min
post-injection (Table 4). The disappearance of GCase activities in
serum is presented as the percentage of 2 min values, as this was
the earliest harvest time point possible. The clearance of both
enzymes in serum had tK=8–11 min (Fig. 1). By 20 min post-
injection, serum activities of injected Vela and Imig were ,10% of
the 2-min values. Concurrent GCase CRIM determinations in
serum showed a similar disappearance profile, with tK,13 min in
both age groups (Fig. 1). When expressed as CRIM-SA, the
decreasing values indicate losses of intrinsic catalytic activity
during prolonged exposure to serum, so that by 20 min the intact
enzyme remaining in serum has ,10% of its original catalytic
value. The enzymes’ CRIM-SA appeared to be somewhat more
stable in serum of 20-wk mice, but the SEs were large and this is
not conclusive. In serum, GCase activities, CRIM, or CRIM-SA
disappearances were similar for Vela and Imig at either 5 or
20 wks of age (p.0.05).
Tissue GCase activities. The uptake and disappearance of
administered Vela or Imig were evaluated in liver, spleen, and
lung. The total recovery of injected activity was based upon organ
and body weights. In 20-wk 9 V/null mice, the peak liver activities
(20 min) of injected Vela and Imig were 2.5- to 3.5-fold greater
than WT levels, and they remained at or above WT levels for 3 h
(Fig. 2A). GCase activity disappeared with tK,100 min and
decreased ,30% within 40 min for either enzyme. This was
followed by a slow decrease to 13–15% of WT by 42 h: this level
of GCase activity was about twice that of saline-injected cohorts
(7.2% of WT). The activity disappearance curves for Vela and
Imig were very similar (p=0.3048). The CRIM levels showed
concordant disappearance profiles, with tK,90–110 min for
either GCase (p=0.857) (Fig. 2A). In comparison to serum, the
CRIM-SA’s of the GCases were stable and did not differ between
Vela and Imig (p=0.46) for 4 h post-injection (Fig. 2A). At 18- or
42-h, the immunoblot signals were weak and not reliable. On the
imunoblots, a non-GCase/non-specific, low molecular weight
band was detected only in liver, including those with 0 ng of
enzyme or at 42 h.
In 5-wk 9 V/null mice, these profiles were similar to those at
20 wks, with some differences. The peak activities (20 min) of Vela
and Imig in liver in 5-wk mice were slightly less than those at
20 wks (,2.5-fold of WT), and they remained at $WT level for
,70–80 min post-injection, vs. ,180 min in 20-wk mice. The
activity disappearances of both enzymes in liver had a tK,60 min
(about 60% of the 20-wk mice), with a ,60% drop within 40 min
(,2 times that of 20-wk mice). A slow decrease to 13–18% of WT
occurred by 42 h (Fig. 2A). No differences in the activity
disappearance curves were evident between Vela and Imig in
the 5-wk livers (p=0.9846). The CRIM disappearance curves
paralleled those for GCase activity. The CRIM-SA was
unchanged during this time course. The enzyme uptake into liver
cells was evaluated by immunofluorescence at 20 min post-
injection. Human GCase signals in liver from Vela- and Imig-
injected mice were located mainly in the periportal region of the
liver and in the interstitial spaces (Fig. 2B). These data indicate
predominate uptake into Kupffer and sinusoidal endothelial cells
of either GCase.
The peak activities of Vela and Imig in spleen of 20-wk 9 V/
null mice were 3- to 4.5-fold WT levels at 20 min post-injection,
and they remained at $WT levels for ,3.5 h. The enzyme
activities decreased by ,40% by 40 min and then smoothly
returned to baseline activity over 42 h (Fig. 3). The GCase protein
disappearance was concordant with the activity (tK,1.0–1.5 h) for
either enzyme (Fig. 3). The CRIM-SA of Vela or Imig in spleen
was stable up to 4 h; by 18–42 h CRIM was not reliably detected.
There were no significant differences between Vela and Imig for
any of these parameters (p=0.55–0.96).
Table 3. Thermostability of Enzyme Activity.
Condition Vela, t1/2 (min) Imig, t1/2 (min) p value
25uC in CP, pH 7.4 118.661.91 122.467.75 0.6617
37uC in CP, pH 7.4 109.260.15 111.562.48 0.4223
25uC + h-serum 176.065.87 186.466.35 0.2562
25uC + m-serum 194.166.11 215.2615.18 0.2273
37uC + h-serum 127.0610.14 127.5610.14 0.9747
37uC + m-serum 138.663.82 147.367.44 0.321
Vela or Imig activities were assayed as described in Methods. The tK was the
time at which GCase activity decreased to 50% of initial values. n=3 to 6 for all
assays.
doi:10.1371/journal.pone.0010750.t003
Table 4. Recovery of Vela or Imig activity in serum and organs of 9 V/null mice
A.
Enzyme Serum
B Liver
C Spleen
D Lung
C
5-wk 20-wk 5-wk 20-wk 5-wk 20-wk 5-wk 20-wk
Imig 65.5363.31 60.2161.76 54.3661.84 71.8662.52 0.2560.25 3.4060.37 0.1260.01 0.2060.06
Vela 63.0664.62 58.1661.61 57.5361.35 60.3662.01 1.8660.06 2.6260.08 0.160.01 0.0460.01
AThe recovery of injected Vela or Imig was calculated as the percentage (% 6 SE) of total serum or whole organ activity at the peak of enzyme activity following a bolus
of 60 U/kg injection.
BThe peak activity in serum was 2 min post injection.
CThe peak activity in liver and lung was 20 min post injection.
DThe peak activity in spleen was at 40 min in 5-wk mice and 20 min in 20-wk mice post injection.
doi:10.1371/journal.pone.0010750.t004
Gaucher Disease Mouse Model
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,2- to 3-fold) and later than in the 20-wk mice (Fig. 3). The
activity disappearances of Vela and Imig were very similar
(p=0.761). The CRIM levels in spleen had a tK,60 min (Imig)
and tK,120 (Vela) (Fig. 3). The splenic CRIM-SA of Vela or Imig
in 5-wk 9 V/null mice was lower (0.2–0.8610
6 nmoles/h/mg
enzyme protein) than that in 20-wk 9 Vnull mice; at 5 wks there
were no significant differences in CRIM-SA between Vela and
Imig (p=0.114).
Overall, as summarized in Table 4, the majority (60–70%) of
injected GCase was localized to the liver in either age group.
Spleens had an uptake of ,2–3% of injected enzymes, but the
peak activities were $2-fold of WT levels at 20 min post-injection.
In comparison, less than 0.2% of injected activities were recovered
Figure 1. Serum disappearance of Vela or Imig in 20-wk (left) or 5-wk (right) 9 V/null mice. GCase activities in serum were measured at 2–
60 min post-injection of Vela (m, solid line) or Imig (N, dashed line). The values are referenced to the 2-min peak values. Serum disappearances of
injected Vela and Imig proteins (CRIM panels) up to 60 min were analyzed by immunoblots (immunoblot panels). Known amounts of Vela or Imig
protein (0.5–6 ng) were loaded on each blot as a reference for quantification of serum Vela or Imig protein for the respective GCases. CRIM-SA was
the specific activity based on the amount of CRIM determined by corresponding immunoblots (CRIM-SA panels). Each data point represents the
mean 6 SE from duplicate assays of three mice in each cohort.
doi:10.1371/journal.pone.0010750.g001
Gaucher Disease Mouse Model
PLoS ONE | www.plosone.org 4 May 2010 | Volume 5 | Issue 5 | e10750Figure 2. Fate and distribution of Vela and Imig in liver of 20-wk or 5-wk 9 V/null mice. (A) GCase activities in liver were assessed at
20 min to 42 h post-injection of Vela (m, solid lines) or Imig (N, dashed lines). The results are referenced to average WT activity (fold change, WT=1).
The disappearance of Vela and Imig activities in liver were also plotted as the percentage of the 20-min peak values (% peak activity panels). The
GCase activities in liver from saline-injected mice were 7.2% (SE=60.006) of WT (X, solid line at the bottom). The disappearances of the Vela and Imig
protein (CRIM panels) up to 42 h post-injection were analyzed by immunoblots (bottom panels, arrows). To control for potential differential
recognition by the rabbit anti-human GCase antibody, known amounts of Vela or Imig protein (0.5–2 ng) were loaded on each blot for quantification
of Vela or Imig protein in liver against their respective standards. CRIM-SA is the specific activity per unit (ng) of CRIM determined by corresponding
immunoblots. Each data point represents the mean 6 SE from duplicate assays of three mice in each cohort. (B) Immunofluorescence of injected Vela
or Imig in liver. Frozen liver sections from 9 V/null mice at 20 min post-injection of saline (left), Vela (middle), or Imig (right) were processed by
Gaucher Disease Mouse Model
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mostly to the liver and that a substantial portion of enzyme (30–
40%) was distributed to other organs or was inactivated/
denatured.
Therapeutic effects
Therapeutic effects were evaluated in 9 V/null mice that were
treated weekly with 5, 15, or 60 U/kg/wk of Vela and Imig for
either 4 or 8 wks. Mice were sacrificed one week after the last
injection, and sera and organs were collected for serologic studies,
GCase activities, GC levels, and quantification of storage cells. At
one week after the last injection, the GCase activities in liver,
spleen, and lung had returned to background levels (not shown).
GC levels in liver, spleen, and lung. GC levels in liver by
week 4 or 8 decreased by 50–70% in mice receiving 5 or 15 U/
kg/wk of Vela or Imig weekly (Fig. 4) compared to saline-injected
controls. In comparison, GC level decreases with 60 U/kg/wk
were ,70% with Imig and ,85% with Vela at week 4, and by
,80–85% for both enzymes at 8 wks (Fig. 4). With 5 or 15 U/kg/
wk doses, no significant differences were noted between the Vela
and Imig groups (p.0.05). However, at 15 U/kg/wk doses, the
Vela-injected mice showed a trend toward greater (,66%)
reductions of GC levels compared to ,55% in Imig injected
mice (p=0.42). By 8 wks, this difference disappeared as WT GC
levels were achieved with either GCase. With 60 U/kg/wk,
incrementally greater decreases in GC levels were observed at
4 wks, and the reduction to near-WT levels was again achieved
using Vela, whereas this was not the case with Imig (p=0.0199).
WT GC levels were achieved and maintained with either GCase
by 8 wks at this dose. There was a ,20% greater GC reduction in
the 4- and 8-wk groups receiving 60 U/kg/wk compared to that in
the 5 and 15 U/kg/wk groups; the results represent a dose
response trend (p.0.05). The decrease to WT levels by 8 wks
obscures any additional differences that might exist between Vela
and Imig.
For all three dosing groups, the GC levels in spleen were
reduced by ,10–15% at 4 wks and by ,20–30% at 8 wks
(Fig. 5A). WT levels were not achieved with any dose, at either
time or with either enzyme. In each dosage group, the reductions
of GC levels by Vela and Imig were similar (all p.0.05). In lung,
the GC lipid levels were unchanged at the doses of 5 and 15 U/
kg/wk (Fig. 5B) with either preparation. However, a suggested
trend toward ,10% decrease of GC was observed in lung at
60 U/kg/wk for either enzyme preparation at 8 wks, but the
results were variable within and among groups (Fig. 5B).
Storage cells. Lipid-laden macrophages—Gaucher cells—
are a hallmark of Gaucher disease. H&E-stained liver sections
showed that storage cells were large, engorged, and pale in color
(not shown). In quantitative comparison to the saline control
group, the number of storage cells in either the Vela- or Imig-
treated mice was significantly decreased in all dosage groups, and
the degree of change correlated with the dose increment and
length of therapy (Fig. 6). Although significant changes from
controls were evident at all doses, times, and enzyme preparations,
60 U/kg/wk nearly eliminated these cells in liver by either 4 or
8 wks (Fig. 6). No significant differences were evident in liver
storage cell numbers between Vela and Imig at any dose (p.0.05).
To evaluate the storage cells in the lung, the sections were
processed for immunohistochemistry using rat anti-mouse CD68
antibody, a macrophage membrane antigen [38]. The lipid-laden
storage cells in lung were generally large cells that stained brown
(CD68-positive), indicating the macrophage origin of these lipid-
laden storage cells. The numbers of storage cells in Vela- and
Imig-treated 9 V/null lungs at any dose were not different from
saline control (data not shown).
The GC levels and numbers of storage cell showed concordant
changes with enzyme administration. However, GC levels in the
liver were still above WT levels at 8 wks of 60 U/kg/wk, even
though the liver was essentially cleared of storage cells, indicating
some excess GC was present in cells that are not typical Gaucher
cells. Such quantitative correlations could not be made in the
spleen as representative matched samples were not available, since
GC and enzyme determinations consumed nearly the entire
spleen. The numbers of storage cells in a few available sections
appeared decreased, but not absent. The spleen GC levels
remained significantly elevated even after 8 wks of 60 U/kg/wk.
Antibody responses
To evaluate the immune responses during ERT, serum for anti-
human GCase IgG was obtained every 2 wks during the 8-wk
trial. Using our mouse anti-human GCase antiserum, the titers of
developing anti-human GCase were determined in each mouse in
a standardized manner. Importantly, because of some differences
in reactivity, Vela or Imig were used as antigen controls for the
respective samples from mice. For the 5 or 15 U/kg/wk doses,
serum anti-GCase IgG signals toward either Vela- or Imig-injected
mice were at background or very low levels from each bleed (not
shown). In the mice receiving the 60 U/kg/wk dose, serum anti-
GCase IgG levels increased ,3-fold (at ,3610
3 dilution) above
background by the 4th injection in .50% of Vela- and Imig-
injected mice (Fig. 7A).
With additional injections, IgG positivity increased in all dosing
groups and several mice died. With the 5 or 15 U/kg/wk doses
only a few mice died, whereas with 60 U/kg/wk doses, 9/42 Vela-
injected and 20/59 Imig-injected mice died following injections
during the 4- to 8-wk period (Table 5). Prior to death, these mice
became immobile and their lips/tails became cyanotic. Most mice
died within 30 to 60 min post-injection. However, placing treated
mice in an oxygen chamber for 20 to 30 min after injection led to
the survival of most of the animals. The mice that succumbed were
immediately dissected, and sera were analyzed for IgE titers and
histology. The H&E sections from lung, heart, spleen, kidney, and
brain did not show evidence of an acute inflammatory response.
Total serum IgE levels from these mice injected with Vela or Imig
were 46.4 to 234.9 ng/ml (n=3) or 115.8 to 239.6 ng/ml (n=3),
respectively (p=0.3626). In comparison, saline-injected 9 V/null
serum values were 6.8 to 8.8 ng/ml (n=6) (Fig. 7B).
Discussion
The advent of enzyme therapy for Gaucher disease about two
decades ago led to a major change in the care and health outcomes
of affected individuals. The use of regular infusions of mannosyl-
terminated GCase has led to remarkable improvements in the
overall health, and visceromegaly, organ dysfunction, and bony
complications experienced by people affected with Gaucher
disease type 1. However, the use of this expensive therapy has
led to controversies surrounding the cost-benefit and the degree of
reversibility of specific manifestations. Such controversies continue
to be based on clinical measurements of organ volume, MRI
immunofluorescence staining with rabbit anti-hGCase antibodies/goat anti-rabbit IgG-FITC. The hGCase signals (green) were located mainly in the
periportal region of the liver acinus in the interstitial spaces between hepatocyte arrays. The magnification was 2006, scale bar =50 mm.
doi:10.1371/journal.pone.0010750.g002
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presumptive biomarkers such as chitotriosidase. Pharmacokinetic
or pharmacodynamic studies have been lacking in humans or
animal models to evaluate the effects on disease processes.
Comparative dose-finding schedules have not been evaluated in
humans because of a reluctance to sample appropriate tissues, and
due to the ethical issues associated with obtaining such tissues for
determination of differential biochemical and histological effects.
Here, mouse analogues of human Gaucher disease with tissue
involvement, including the presence of Gaucher cells and excess
Figure 3. Disappearance of Vela or Imig in spleen of 20-wk (left) or 5-wk (right) 9 V/null mice. GCase activities in spleen were determined
from 20 min to 42 h post-injection and represented as fold of WT (WT=1) as in Figure 2. The disappearances of Vela or Imig activities were plotted as
fold WT (activity panels) or from the 20-min (20-wk) or 40-min (5-wk) peak values (% peak activity panels). The GCase activities in spleen from saline-
injected mice were 8.1% (SE=60.017) of WT (X, solid line at the bottom of top panels). Disappearances of Vela or Imig proteins (CRIM panels) up to
42 h post-injection were analyzed by immunoblots as per Figure 2.
doi:10.1371/journal.pone.0010750.g003
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terminated GCases for treatment effects and dose response as well
as pharmacokinetics and pharmacodynamics. Although not strictly
comparable to humans, the differential immunological responses
of the mice to the infusions of human enzymes were compared
with the two agents.
The two preparations of mannosyl-terminated GCase are highly
similar for in vitro kinetic properties and interactions of their active
sites with substrates and inhibitors. The amino acid sequences of
the two enzymes differ by one amino acid at position 495, in which
Imig contains a histidine (R495H) substitution for an arginine
(R495), the naturally occurring amino acid that is present in Vela
[39]. The present results are consistent with those from previous
studies in which GCase was expressed in the baculovirus system
[28,29]; the R495H had no influence on the in vitro kinetic
properties or stability of the enzyme relative to the R495 GCase
[28,29]. In particular, the kinetic constants for interaction with
either reversible (iminosugars) or irreversible inhibitors (CBE and
2,4-DNPFG) were similar. Of particular interest was that the
GCase’s interactions with the very potent reversible inhibitor IFG
(Ki,20 nM) were similar. This inhibitor is known to induce a
significant conformational change in loop 1 of GCase, indicating
that at least at this level, the two enzymes have similar movements
[35]. In vitro, enhancers of GCase activity, i.e., saposin C and the
negatively charged phospholipids showed no differences between
these GCases or those previously reported [29,40]. The catalytic
rate constant of Vela was consistently greater (6–10%) than that
for Imig based in the quantification of CRIM or active sites using
the single-turnover substrate DNPFG. These differences were not
significant (p=0.85) and there was some batch-to-batch variation
due to storage.
A significant difference in structure between the Imig and Vela
is the presence of a greater number of mannosyl residues attached
to the latter as a result of the kifunensine treatment of the
producing cells. This molecule inhibits ER a-mannosidase I and
prohibits the cleavage of extended mannosyl structures present on
the nascent GCase prior to its modification and remodeling in the
Golgi [41,42]. The predominant number of mannoses on Vela is 9
[43]. In comparison, Imig contains a smaller number (,3) of
mannoses that are exposed by sequential exoglycosidase treatment
following expression in CHO cells and purification [44]. These
differences in oligosaccharides had no effect on the in vitro
stabilities or the kinetic properties of either enzyme. These results
are similar to those obtained previously [44].
The pharmacokinetic and pharmacodynamic studies show
essential similarities between Vela and Imig administered as
intravenous boluses. The majority of injected enzyme can be
recovered from the liver ($60%) and smaller amounts in the
spleen. Immunofluorescence showed that the cellular distribution/
concentration in the liver was to/in interstitial cells, including
endothelial cells and Kupffer cells, with low-level discrete
fluorescence signals over the hepatocytes. The distribution of
mannosyl-terminated GCases within livers of normal mice showed
parenchymal hepatocyte as well as endothelial cells and Kupffer
cell uptake [9,44,45]; this is likely the case here also. Although not
formally evaluated, the concentration of human GCase fluores-
cence signals in the periportal regions and interstitial areas
indicates a preferential, but certainly not exclusive, uptake into
endothelial and Kupffer cells. This is reflected in the nearly
complete disappearance of storage cells in liver, but GC levels
remaining elevated at 5 and 15 U/kg/wk with either enzyme even
at 8 wks of treatment. Previous studies with acid lysosomal lipase
Figure 4. Effect of Vela or Imig on GC levels in liver. 9 V/null mice were injected with 5, 15, or 60 U/kg/wk of Vela (m) or Imig (N) for 4 wks (top
panels) or 8 wks (bottom panels). GC liver levels were quantified by LC/MS and expressed as the percentage of the saline-injected group. WT mice (¤)
are provided for reference. GC values in accompanying data tables represent the mean 6 SE from 5–13 mice in each cohort. Liver GC values for Vela-
or Imig-treated mouse cohorts were analyzed by t-test.
doi:10.1371/journal.pone.0010750.g004
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the macrophage mannose receptor, mannosyl-terminated enzymes
can be delivered to Kupffer cells, endothelial cells, and hepatocytes
in affected mice [45]. No differences were observed in tissue
distribution between Vela and Imig using immunblot assays, nor
did there appear to be significant preferential differences by
immunofluorescence in cellular uptake. Of significance is the
essential lack of intravenously administered GCase recovery from
the lungs of the affected mice. In these 9 V/null mice, large
numbers of storage cells accumulate interstitially and in the alveoli.
Very little, if any, of the intravenously administered enzymes could
be detected in the lungs of these affected mice at any time point.
This is consistent with the anecdotal observations of persistent
alveolar storage cells in lungs of a Gaucher disease patient even
after 15 months of ERT via right atrial catheters [24].
Following single intravenous administrations of equivalent
amounts of enzyme to these affected mice, the half-lives of
disappearance for the enzymatic activity and the GCase protein
were determined in a variety of tissues. Both showed similar
disappearances of enzymatic activity and protein in all the tissues.
In plasma where GCase is known to be unstable due to the
exposure to pH 7.4, the catalytic rate constant (approximated by
CRIM-SA) of the enzymes decreased with time. By ,20 min after
injection, the intrinsic activity of the enzyme remaining in plasma
was ,5% of that in the original injected doses for either enzyme. It
should be noted that with time, the amount of enzyme protein and
Figure 5. Effect of Vela or Imig on GC levels in Spleen (A) and Lung (B). The graphs contain the GC values (mean 6 SE) from 7–16 mice in
each dosing cohort relative to the values from saline injected mice. The symbols and analysis methods are the same as in Figure 4.
doi:10.1371/journal.pone.0010750.g005
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difficult at later time points. The disappearances of GCase activity
and protein in the tissues were similar between the two enzyme
preparations. Of importance, even though the half-lives in liver
and spleen were 1–1.5 h, the exogenous GCases in liver and
spleen remained stable in terms of their intrinsic catalytic activity
as assessed by CRIM-SA. This implies that once delivered to the
lysosomes of the tissues, the administered GCases remain in a
stable catalytic form with the same intrinsic activity as the
administered enzyme for significant periods of time. Thus,
although the amount of enzyme decreases significantly in the
tissues, the enzyme that retains normal activity can contribute
significantly to the amount of residual activity in these mice.
Also, only minor differences were determined between mice at
5 wks compared to those with more advanced disease at 20 wks of
age. These results imply that the degree of disease involvement,
particularly of the liver, has small effects on the distribution or
degradation of the administered enzyme. Of note was the more
rapid disappearance of either administered GCase activities and
proteins in the 5- vs. the 20-wk mice. A small difference was also
appreciated between the two GCases, with Vela being cleared
somewhat more rapidly from the 5-wk livers than Imig. No
difference in this parameter was noted between these GCases in
the 20-wk mice. For either enzyme, the activity and protein
returned to essentially baseline levels by 20–42 h. Immunologi-
cally, the human enzyme could be distinguished from the intrinsic
mouse enzyme by the use of a specific antibody that does not react
with the small amount of mouse enzyme present in this model.
These results suggest that, although minor, the more rapid
clearance of the GCases from the liver in the less involved mice
could impact the continued improvement in patients, e.g., as their
overall disease, particularly the liver involvement, is reversed, the
length of time that their organs experience a therapeutic level of
the GCases could be shortened and the rate of reversal could slow
[8,18].
Significant discussions have been devoted to the dose response
of patients to the GCase therapy. Recent studies based on registry
data and direct clinical observations have resolved the issue of dose
response to Imig by showing incremental improvements in clinical
parameters based on increasing doses of Imig [18,46]. However,
essentially no data are available on the effects at a tissue level of
biochemical or histological aberrations for different doses. The
accumulation of Gaucher cells and GC in 9 V/null mice provided
the opportunity to evaluate dose response at a tissue level and also
to conduct comparative studies of the two GCases at three
different doses; the dose range was 12-fold (5–60 U/kg/wk). At a
histological level, when administered to either 5-wk or 20-wk mice,
a difference in the quantitative liver (p=0.28–0.84) or lung (data
not shown) cytopathies was not observed when comparing the
effects of either GCase. Over a period of 8 wks with weekly dosing,
essentially a complete clearance of GC and Gaucher cells from the
liver and significant clearance of GC from the spleen were
observed. This effect was dose- and time-incremental, so that by
4 wks a significant change had occurred; This was most evident in
the liver at 60 U/kg/wk where Vela reduced GC to WT levels,
whereas Imig did not (p=0.0199). By 8 wks of treatment this
difference was no long apparent (p=0.176) as Imig had, by then,
reduced the GC in the liver to WT levels. The lungs, particularly
the alveolar Gaucher cells, were not cleared to any significant
extent by either enzyme. A difference of ,10% in cellular
Figure 6. Reduction of liver storage cells with Vela or Imig administration. Liver storage cell quantification was done after administration of
various doses of Vela or Imig for 4 or 8 wks. Liver H&E sections from these mice were examined by light microscopy, and storage cells in 10
independent fields from each section were counted. The mean (6SE) values are shown in the data tables. Liver sections from saline-treated mice (.)
were processed in parallel. Storage cells in Vela (m) or Imig (N) treated mice (n=6–14 mice) in each cohort were analyzed by t-test.
doi:10.1371/journal.pone.0010750.g006
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there was substantial variation in cell count number, and this
difference in Gaucher cell clearance was not significant. A lack of
effect in the lungs is not unexpected, since human studies showed
persistence and progression of alveolar Gaucher cells even with
Imig infusions directly into the right atrium, thereby providing
Figure 7. Anti-human GCase IgG (A) and IgE (B) in Vela- or Imig-treated 9 V/null mice. (A) 9 V/null mice that received Vela (solid bars) or Imig
(open bars) were bled prior to every second injection, and mouse anti-human GCase IgG levels were assessed by ELISA. The OD 490 nm (Y-axis) readings
from each mouse (X-axis) are presented. The number of tested (n) in each group is listed below the graph with the number of mice that died indicated as
(-n), e.g., (n=15, 21) means that 15 mice were assayed and that one mouse in that group had died from the injection related reaction, and the empty
lane on the graph represents the death of those mice from which no serum was obtained. Assays were in triplicate; control samples were from saline-
injected (hatched bars) mice and were conducted in parallel. The standards (grey bars) were determined with mouse anti-human GCase antiserum (3–
10610
3 dilutions) and were used as a reference. (B) Total serum IgE levels in Vela- or Imig-treated mice that experienced acute immunological/
anaphylactic reactions. Shown are results from serum samples from three mice that died with apparent anaphylactic reactions following 4 or 5 injections
of Vela (solid bars) or Imig (open bars) with a 60 U/kg/wk dose. The values were quantified using pure mouse IgE protein as a standard and plotted as ng
IgE/ml. Assays were conducted in triplicate; control samples were from saline-injected mice (hatched bars) and were conducted in parallel.
doi:10.1371/journal.pone.0010750.g007
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enzyme [24]. The basis for this lack of alveolar effect is unclear,
but may be due either to enzyme not entering the alveolar space or
to the enzyme being carried into the alveoli by cells with long
residence times, during which the administered GCase may be
degraded. The absence of enzyme would leave the alveolar
macrophages deficient in GCase for the majority of their life spans.
The source of the lung substrate is unknown, but is probably due
to local synthesis within the bronchiorespiratory tree.
Concordant with the changes in Gaucher cell number within
the tissues were decreases in GC content. In both liver and spleen,
significant decreases in GC content were observed at any of the
doses. As with the cell counts the change in lipids was proportional
to the dose given with the higher doses showing more substantial
clearance than the dose at 5 U/kg/wk. The 5 U/kg/wk effect was
not statistically different between the two enzyme preparations.
However, with 15 and 60 U/kg/wk at 4 wks, Vela affected greater
degrees of decrease of GC in the liver; the latter dose was
statistically significant at 4 wks. This effect at 4 wks is the only
statistically significant difference at a tissue or a biochemical level
between these two enzyme preparations. Importantly, the effects
in liver and spleen were significant at all three dosage levels, and
the lack of effect in the lungs was the same for all three dosages.
These studies cannot determine if longer-term therapies or
different modes (e.g., slow infusion) of administration would
permit the clearance of Gaucher cells and GC from the lung, but
the human studies suggest that even long-term intravenous
administration on an intermittent basis does not lead to clearance
in the lungs. Evidently, alternatives for this rare manifestation in
humans will have to be developed. To this end, the clearance of
the alveolar Gaucher cells in the 9 V/null mouse receiving a
potent GC synthase inhibitor Genz 112638, i.e., substrate
synthesis inhibition therapy, has been observed [47].
Not unexpectedly, the mice receiving human GCase developed
antibodies to this antigen in almost all circumstances. IgG was
detected in many mice, and a significant number of mice
developed an anaphylactic-like reaction after several doses of
either enzyme. Indeed, IgE was present in a number of mice from
whom sera were available, suggesting an anaphylactic mechanism.
The clinical parameters of cyanosis—difficulty breathing and
tachycardia—were consistent with this. Although there were no
statistically significant differences in antibody (IgG or IgE)
positivity rates (p=0.3636), there was a significant difference in
the number of mice that died during the studies while receiving
Imig compared to Vela. Whether this increased death rate was due
to the enzyme administration procedure or some immunologic
reaction to Imig as compared to Vela is not known. However,
these studies suggest that at least in the mouse, there may be some
antigenic recognition differences between the two enzyme
preparations leading to elicitation of the mouse antibody response
and culminating in the death of some of the mice. Not
unexpectedly, the antibody positivity rate in these mice was much
greater than that seen in humans, which has remained at ,13–
15% for Imig for the past ,20 years [32]. If transferable to
humans with Gaucher disease type 1, Vela might be expected to
have lower antibody positivity rates. Thus, while these antibody
responses are not exactly comparable between humans and mice,
they are suggestive of potential differences that might be elicited by
either the enzyme or the other components in the clinical
preparations of the supplied enzyme.
In summary, these studies show similar effect of Vela and Imig
at several different doses, at a therapeutic level, and at different
ages with differing degrees of involvement. There do not appear to
be any particular adverse effects of the administered enzyme
secondary to antibody production, although there were IgE-
mediated reactions in these mice receiving human GCases leading
to death. Furthermore, these studies demonstrate clearly that both
enzymes achieved similar therapeutic effects, with the doses and
route of administration used here, and at different ages or degrees
of involvement of the mice. Significantly, the lungs are not altered
in their degrees of involvement by enzyme therapy at any dose
over an 8-wk period in this mouse model.
Materials and Methods
Materials
The following were from commercial sources: Imiglucerase
(Imig, Lot#A7021H04, Genzyme, Cambridge, MA). Velaglucer-
ase alfa (Vela, Lot#FEC06-002, HGT/Shire, Cambridge, MA).
Preservative-free, sterile water (Hospira, Lake Forest, IL). 0.9%
sodium chloride for injection (Abraxis Pharmaceutical, Schum-
burg, IL). Conduritol B epoxide (CBE), deoxynojirimycin (dNM)
and sodium taurocholate (TC) (Calbiochem, San Diego, La Jolla,
CA). 4-methylumbelliferyl-b-D-glucopyranoside (4-MU-Glc; Bio-
synth AG, Switzerland). Isofagomine-HCl (IFG), C4-, C9-, and
C12-dNM (Toronto Research Chemicals, Toronto, Canada). 2,4-
dinitrophenyl-2-fluoro-2-deoxy-glucopyranoside (DNPFG), Triton
X-100 (TX), castanospermine (CS), and SIGMAFAST OPD
(Sigma, St. Louis, MO). Brain phosphatidylserine (BPS), C12-
NBD, and C12-NBD-glucosylceramide (NBD-GC) (Avanti Polar
Lipids, Alabaster, AL). Cathepsin D (EMD Biosciences, Gibbs-
town, NJ). Isoflurane (Abbott Lab, Abbott Park, IL). Heparinized
microhematocrit capillary tubes (Cardinal Health, Dublin, OH).
Hybond ECL Nitrocellulose Membrane (Amersham, Piscat-
away, NJ). 4–12% gradient Bis-Tris Gel (Invitrogen, Carlsbad,
CA). BCA Protein Assay Kit, Peroxidase-Conjugated Goat Anti-
rabbit IgG, M-Per Mammalian Protein Extraction Reagent, ECL
Kit, and Purified Mouse IgE (PIERCE, Rockford, IL). Mouse IgE
Table 5. Injection-related deaths
A.
Enzyme No-oxygen Oxygen
B Total number
Mice
C Death (%)
D Mice
C Death (%)
D Mice
C Death (%)
D
Vela 31 7 (22.6%) 11 2 (18.2%) 42 9 (21%)
Imig 31 15 (48.4%) 28 5 (17.9%) 59 20 (34%)
A9 V/null mice were injected with 60 U/kg of Vela or Imig, once a week for 8 weeks; the mouse death number and percentage (%) of total injected mice in 8-wk courses
are presented.
BOxygen chamber was applied for minimum 20 min to the mice receiving Vela or Imig.
CThe number of injected mice in each cohort;
DThe number and percentage of dead mice from total injected mice.
doi:10.1371/journal.pone.0010750.t005
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mouse IgG (Dako, Denmark). Rat anti-mouse CD68 and goat
anti-rat-HRP (Serotec, Raleigh, NC). Goat anti-rabbit biotinylated
and streptavidin-Alexa Fluor-610 (Molecular Probes, Irvine, CA).
Methods
In vitro enzymology studies. Vela and Imig were compared
for kinetic properties as described [29]. Briefly, the standard GCase
activity assay contained final concentrations of 50 mM citrate/
phosphate, pH 5.5, 0.25% TC, 0.25% TX, and 4 mM 4MU-Glc
in 200 ml. The reactions were stopped after incubation (30–60 min,
37uC) using 0.9 M ethylenediamine, pH 11.0 (100 ml). Standard
curves for 4-MU fluorescence yield were generated for each assay
with Ex/Em 460/515 nm (Molecular Dynamics SpectraMax
GeminXS spectrofluorometer). Vmax and Km were calculated
from Lineweaver-Burke equations using several concentrations
(0.25–10 mM) of 4MU-Glc. For the reversible competitive
inhibitors, Ki was calculated from IC50=K i (1+ [I]/[Km]). The
IC50 or Ki values for various inhibitors (dNM and its derivatives,
CBE, CS, IFG, DNPFG) were determined using 4MU-Glc as
substrate. Activities with the NBD-GC substrate were as described
[48]. Enzyme assays with saposin C (0–500 nM/0.5 mMB P S )a n d
BPS (0–2 mM) were as described [29,40]. Saposin C was expressed
in E. coli and purified as described [40]. For thermostability
assessments, equal amounts of Vela and Imig activities were added
to 50 mM citrate/phosphate, pH 7.4, with or without human/
mouse serum, and incubated for 0–240 min at 25 or 37uC. The pH
optimum profiles were developed using 50 mM citrate/phosphate,
pH 4.4–7.2. Protease susceptibilities of the two GCases were
evaluated by cathepsin D (1–2 mM) digestion in 25 mM sodium
acetate, pH 4.8, 50 mM NaCl, 1.25 mM EDTA, 1.25 mM DTT
using 200 ng of Vela or Imig at 37uC for 4 h [29]. All assays were
conducted in triplicate and repeated at least twice. The amounts of
intact enzyme were determined from density measurements on
immunoblots and were compared to the initial amounts. The ratios
of intact enzyme with and without cathepsin D were used as
indicators of the enzyme’s proteolytic susceptibility.
Mice with point-mutated GCase. D409V/null (9 V/null)
mice and WT littermates were of mixed genetic backgrounds [33].
The CCHMC Institutional Animal Care and Use Committee
(CHCMC IACUC) reviewed and approved these studies under
protocol 7C02017. All mice were housed under pathogen-free
conditions in the barrier animal facility and according to IACUC
standard procedures at Cincinnati Children’s Hospital Research
Foundation. Mice were monitored daily and weighed weekly. In
visceral tissues, the GCase activities were ,1–5% of wild-type
levels. Mice at 5 and 20 wks of age were used for these studies.
Enzyme preparation for injection. Vela and Imig were
reconstituted with sterile water under sterile conditions according
to manufacturers’ instructions. The reconstituted concentrations of
Vela and Imig were 100 U/ml and 40 U/ml, respectively. A unit
(U) of GCase activity is 1 mmole/min of 4-MU cleaved from 4-
MU-Glc at 37uC, in 50 mM citrate/phosphate, pH 5.5, in the
presence of 0.25% TC and 0.25% TX [28]. Aliquots of
reconstituted enzymes were stored at 280uC that were diluted
with 0.9% NaCl just prior to injection. Vela and Imig activities
were determined on the day of injection and were used for pre-
and post-injection activity calculations.
Enzymes were injected intravenously via tail vein under sterile
conditions using a U-100 insulin syringe with a 28Ga needle
(Becton Dickinson). Mice were anesthetized with isoflurane. For
the PK/PD studies, two age groups (5 and 20 weeks old) of 9 V/
null mice (3 mice per cohort) were injected with 60 U/kg of Vela
or Imig. Samples were obtained at 2, 5, 10, 20, and 40 min and at
1, 2, 4, 18, and 42 h. For therapeutic studies, 9 V/null mice were
administered doses of 5, 15, or 60 U/kg/wk of Vela or Imig
weekly for 4 or 8 wks.
Tissue and serum collection and GCase assay. Blood
samples from anesthetized mice were taken from the retro-orbital
plexus. Serum was separated from clotted blood (0.5 h, 4uC) by
centrifugation at 12,000 rpm (15 min). Mice were then euthanized
by CO2 narcosis and perfused with normal saline (2 to 3 times
blood volume) prior to tissue harvest. Tissues (liver, spleen, lung,
and brain) were harvested immediately, rinsed with saline, blotted
dry, snap frozen, and stored at 280uC for enzyme, lipid,
histological, and immunoblot analyses.
Tissue lysates were prepared as described [23]. Protein
concentrations were determined using the BCA Protein Assay
Kit. For GCase activity assays, tissue lysates were pre-incubated in
the presence or absence of CBE (2 mM, 30 min, room
temperature) prior to the addition of 4MU-Glc substrate to
estimate the amount of tissue non-acid b-glucosidases that cleave
4-MU-Glc [28,29]. For serum GCase activity assays, 5 mlo f
freshly collected serum was diluted in 10 ml of saline, and 5–25 ml
aliquots were used for assay. GCase activities are expressed as
nmoles/h/mg of tissue protein or nmoles/h/ml of serum. Control
non-injected or saline-injected and WT mouse tissues were
processed in parallel.
Immunoblots, CRIM, and CRIM-SA. CRIM-SA was
based on the amount (ng) of intact GCase (Mr,60,000 to
63,000) CRIM quantified from immunoblots using polyclonal
antibody [41]. For these analyses, tissues were extracted (1:5, wt/
vol) in M-Per with a dounce homogenizer (10–12 strokes). Equal
amounts of supernatant protein from tissues or equal volumes of
serum at each time point were subjected to SDS-PAGE. For
immunoblots, membranes were pre-treated with 3% BSA in PBS-
0.05% Tween-20 (1 h) incubated with the rabbit anti-human
GCase antibody and, then, peroxidase-conjugated goat anti-rabbit
IgG in PBS-0.05% Tween-20. The known amounts of Vela or
Imig standard (0.5–6 ng) were mixed with serum aliquots or tissue
lysates from saline-injected 9 V/null mice and loaded onto each
gel for quantification standards and as background controls. The
immunoblots were developed using ECL kits, and the amount of
human GCase cross reacting immunological material (CRIM) in
each lane was quantified using ImageQuant5.2 software. Known
amounts of Vela or Imig proteins were used as standards for the
respective samples from injected mice.
Lipid analyses. GC levels in liver, lung, and spleen from
9 V/null and WT mice were quantified by LC/MS-MS
(Lipidomic Core, University of South Carolina). The GC levels
were normalized to protein in the same lysates used for GCase
activity and expressed as the percentage change relative to the GC
levels of matched samples from saline-injected mice. WT lysates
were used as a reference. The Student’s t-test was used for
statistical comparisons.
Storage cells. Duplicate tissue sections were fixed in 10%
formalin for hematoxylin and eosin (H&E) staining and in 4%
paraformaldehyde-PBS, pH 7.4 for immunohistochemistry with
CD68 antibody [49] and examined using a Zeiss microscope
equipped with SPOT Advance software (SPOT Diagnostic
Instruments, Inc.). Large pale cells ($5 mm, WT,5 mm) in
H&E-stained liver sections and CD68-positive macrophages in
lung sections were counted manually in 10 randomly selected
fields (305 mm 6228 mm/field) from each mouse. Mice (n=6–14)
in the Vela-, Imig-, or saline-treated groups were used, and the
resultant data were analyzed using the Student’s t-test.
Detection of mouse anti-Vela or -Imig IgG and total
IgE. For the 8-week therapeutic study, 9 V/null mice were
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every other week, before enzyme injections, for GCase antibody
analyses. ELISA was used to determine the mouse anti-GCase IgG
levels. Immulon-4 plates (96-well) were coated with 100 ng of Vela
or Imig and processed [50]. Mouse serum samples (100 ml, 1:4
dilutions) were used for analyses with pre-immune serum as
negative controls. Standard curves were generated with mouse
polyclonal anti-human GCase antiserum (1:50 to .1:100,000
dilution) on the same plates. The reaction was stopped by addition
of 3 M H2SO4 (50 ml) per well and read at 490 nm (Molecular
Dynamics SpectraMax GeminXS). The absorbance values were
expressed as endpoint titers of each sample and normalized using
the standard curve. For detection of mouse total serum IgE, the
mouse samples were analyzed with the Mouse IgE ELISA kit as
above [50]. Biotinylated anti-mouse IgE monoclonal antibody and
streptavidin-horseradish peroxidase conjugate (SAv-HRP) were
used for detection. Purified mouse IgE was used as standard for
quantification.
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